Sekar Kathiresan, MD, is co-founder and chief executive
officer at Verve Therapeutics. He has focused his career on understanding the
inherited basis for heart attack and leveraging those insights to improve the
care of cardiovascular disease. Based on his groundbreaking discoveries in
human genetic mutations that confer resistance to cardiovascular disease, Sek
co-founded Verve Therapeutics with a vision to create a pipeline of
single-course, gene editing therapies aimed at addressing the root causes of
this highly prevalent and life-threatening disease.
